{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-003003","form_type":"8-K/A","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.178478+00:00","generated_at":"2026-06-06T09:03:19.153233+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra completes Acer acquisition; pro forma net loss $59.5M for 9-mo 2023","bullets":["Pro forma net loss of $59.5M for nine months ended Sep 30, 2023; $80.7M for FY 2022.","Acer acquisition closed Nov 17, 2023; exchange ratio 0.1210 Zevra shares per Acer share plus CVR.","Pro forma shares outstanding ~37.8M; Zevra issued ~2.96M shares for Acer equity.","Zevra purchased Acer's SWK term loans ($18.2M) and Marathon convertible notes ($12.0M).","Bridge loan of $10M provided to Acer; $1.5M anniversary payment due to Relief Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-003003","json":"https://secwatch.observer/filing/0001437749-24-003003.json","markdown":"https://secwatch.observer/filing/0001437749-24-003003.md","text":"https://secwatch.observer/filing/0001437749-24-003003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924003003/0001437749-24-003003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924003003/zvra20240126_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:03:19.153233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}